Analysts Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Price Target at $20.29

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been assigned an average recommendation of "Buy" from the nine ratings firms that are covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $20.29.

A number of equities analysts have recently weighed in on TRVI shares. Raymond James Financial upgraded Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and upped their target price for the company from $9.00 to $29.00 in a report on Monday, March 10th. HC Wainwright began coverage on shares of Trevi Therapeutics in a research report on Wednesday, May 28th. They set a "buy" rating and a $21.00 price objective on the stock. Needham & Company LLC reiterated a "buy" rating and issued a $24.00 target price on shares of Trevi Therapeutics in a research report on Tuesday, May 20th. B. Riley reissued a "buy" rating and set a $20.00 target price (up previously from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Finally, D. Boral Capital restated a "buy" rating and set a $21.00 price target on shares of Trevi Therapeutics in a report on Monday, June 2nd.

Institutional Trading of Trevi Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Summit Investment Advisors Inc. raised its holdings in shares of Trevi Therapeutics by 84.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock valued at $26,000 after purchasing an additional 2,894 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Trevi Therapeutics in the fourth quarter worth $49,000. Strs Ohio acquired a new position in Trevi Therapeutics during the first quarter worth $52,000. Squarepoint Ops LLC acquired a new position in Trevi Therapeutics during the fourth quarter worth $58,000. Finally, Two Sigma Advisers LP bought a new position in Trevi Therapeutics during the fourth quarter valued at about $66,000. 95.76% of the stock is owned by institutional investors.

Trevi Therapeutics Trading Down 0.1%

NASDAQ:TRVI traded down $0.01 during trading hours on Thursday, hitting $5.66. 137,943 shares of the stock traded hands, compared to its average volume of 1,389,442. The firm has a 50 day moving average price of $6.34 and a 200 day moving average price of $5.30. The firm has a market cap of $663.27 million, a price-to-earnings ratio of -12.60 and a beta of 0.59. Trevi Therapeutics has a fifty-two week low of $2.36 and a fifty-two week high of $7.48.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.04. Research analysts predict that Trevi Therapeutics will post -0.49 EPS for the current year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.